<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237493</url>
  </required_header>
  <id_info>
    <org_study_id>671201612222</org_study_id>
    <nct_id>NCT04237493</nct_id>
  </id_info>
  <brief_title>Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan</brief_title>
  <official_title>Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every lunar year, during the month of Ramadan, Muslims abstain from food and drink between
      dawn and nightfall. People with type 2 diabetes who fast during Ramadan are at an increased
      risk of acute glycemic complications. Our aim is to investigate the effect of dosage
      reduction of four glucose-lowering multidrug regimens on the incidence of acute glycemic
      complications in people with type 2 diabetes who fast during Ramadan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">July 24, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>29 days of Ramadan</time_frame>
    <description>Incidence of hypoglycemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperglycemia</measure>
    <time_frame>29 days of Ramadan</time_frame>
    <description>Incidence of hyperglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetic ketoacidosis</measure>
    <time_frame>29 days of Ramadan</time_frame>
    <description>Incidence of diabetic ketoacidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperosmolar hyperglycemic state</measure>
    <time_frame>29 days of Ramadan</time_frame>
    <description>Incidence of hyperosmolar hyperglycemic state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">687</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Low-dosage therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular-dosage therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Glimepiride (Low Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Glimepiride (PO; 1.5 or 3 mg [75% of the pre-Ramadan dose]; OD [with Ifṭār])</description>
    <arm_group_label>Low-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Vildagliptin (Low Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Vildagliptin (PO; 50 mg; OD [with Ifṭār])</description>
    <arm_group_label>Low-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Insulin Glargine U100 (Low Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Insulin Glargine U100 (SC; 9-33 units [75% of the pre-Ramadan dose]; OD [at 10 P.M.])</description>
    <arm_group_label>Low-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD [at 10 P.M.])
Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr [75% of the pre-Ramadan doses])</description>
    <arm_group_label>Low-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Glimepiride (Regular Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Glimepiride (PO; 2 or 4 mg [100% of the pre-Ramadan dose]; OD [with Ifṭār])</description>
    <arm_group_label>Regular-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Vildagliptin (Regular Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Vildagliptin (PO; 50 mg; BID [with Ifṭār and with Suḥūr]])</description>
    <arm_group_label>Regular-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Insulin Glargine U100 (Regular Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Insulin Glargine U100 (SC; 11-44 units [100% of the pre-Ramadan dose]; OD [at 10 P.M.])</description>
    <arm_group_label>Regular-dosage therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)</intervention_name>
    <description>Metformin (PO; 850 mg; BID [with Ifṭār and with Suḥūr])
Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD [at 10 P.M.])
Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr [100% of the pre-Ramadan doses])</description>
    <arm_group_label>Regular-dosage therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prospective participant is a returning patient with type 2 diabetes;

          -  Prospective participant expressed an intention to fast during Ramadan;

          -  Prospective participant has been compliant with one of four glucose-lowering multidrug
             regimens for at least the past three months.

        Exclusion Criteria:

          -  Prospective participant is a pregnant, postpartum, breastfeeding, or eumenorrheic
             woman;

          -  Prospective participant has experienced diabetic ketoacidosis or hyperosmolar
             hyperglycemic state within three months;

          -  Prospective participant has received niacin or corticosteroids within one month; and,

          -  Prospective participant has any history of recurrent hypoglycemia, hypoglycemia
             unawareness, chronic renal insufficiency (stages IV or V), liver cirrhosis,
             uncontrolled epilepsy, depressive disorder, bipolar disorder, psychotic disorder, or
             cognitive dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman A. Zayed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Jordan School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <state>Amman Governorate</state>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Ayman A. Zayed, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Fasting</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Diabetic Ketoacidosis</keyword>
  <keyword>Hyperglycemic Hyperosmolar Nonketotic Coma</keyword>
  <keyword>Metformin</keyword>
  <keyword>Glimepiride</keyword>
  <keyword>Vildagliptin</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Insulin, Regular, Human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

